

ASX ANNOUNCEMENT

ASX Code: ESE

30 November 2018



eSense Lab Appoints New Chairman and Non-Executive Director amid Commercialisation Drive

Investment Highlights

- Appointment of Mr Piers Lewis as Chairman and Mr Amit Edri as a Non-Executive Director
- Mr Lewis has over 20 years' global corporate experience in the resources, banking and technology sectors
- Mr Edri has extensive experience in the medicinal cannabis industry and was COO of a large-scale medical processing and distribution company in Israel
- The Company is in midst of accelerating the commercialisation of its innovative plant-based products

Life science company eSense-Lab Limited (ASX:ESE) ("eSense" or the "Company") is pleased to announce the appointment of Mr Piers Lewis as Chairman and Mr Amit Edri as a Non-Executive Director.

Both appointees have significant corporate experience which will aid in accelerating the Company's commercialisation of its innovative plant-based products. These commercialisation activities include eSense's recently announced commercial supply agreement with E-Quits, one of the largest companies operating in the UK e-liquid market [ASX Announcement: September 23, 2018].

Piers Lewis

Mr Lewis has over 20 years' corporate experience in finance, banking, management and M&A in the resources, banking and technology sectors in Australia, Asia and Europe.

He currently serves on the board of Dawine Limited (ASX:DW8) and Cycliq Group (ASX:CYQ), and is Company Secretary for Grange Resources (ASX:GRR) and Ultima United (ASX: UUL).

In 2011, Mr Lewis founded Smallcap Corporate, a corporate advisory services company providing service to more than a dozen listed and unlisted clients.

He has completed a Bachelor of Commerce degree at the University of Western Australia and qualified as a Chartered Accountant from Deloitte in 2001 and is a member of the Chartered Secretaries of Australia.

Amit Edri

Mr Edri has extensive experience in the medicinal cannabis industry, having served as an Independent consultant for several International medical cannabis companies. Consulting on business development, investment opportunities, and strategy. Amit was the COO of a large-scale medical cannabis processor in Israel.

In 2013 he built a medical cannabis Vaporizers company from scratch, as the founder of this own company, he drove the strategic initiatives of a start-up; fused the business, financial, and technology interests of the company into cohesive operations and led the business through market unpredictability, cutthroat competition, and economic turmoil.

Amit also had a unique career in the Israeli military, gaining the rank of Major with the Israeli Special Air Force Unit.



eSense's CEO Haim Cohen said: "I am extremely pleased with the appointments of Piers Lewis and Amit Edri to the Board of eSense. With the continued commercialisation of eSense products it is important to have directors on the Board with managerial and financial experience to assist and advise the Company's management. Mr Lewis and Mr Edri are important parts of our leadership restructure and I am confident they will have a significant impact on our operations. We look forward to updating the market on the continuation of our activities and successes."

ENDS

For further information, please contact:

Company Secretary

Ian Pamensky
+61 414 864 746
ian@cfo2grow.com.au

Media & Investor Enquiries

Julia Maguire
+61 419 815 386
julia@thecapitalnetwork.com.au

Corporate Advisor

EverBlu Capital
+61 2 8249 0000
info@everblucapital.com

About eSense-Lab | Registered Office: Level 14, 330 Collins Street, Melbourne, Victoria, Australia, 3000

eSense-Lab Ltd (ASX:ESE) is a life sciences research and development company creating natural plant-based products that heal and delight. Headquartered in Israel, eSense-Lab combines genetics, mRNA, protein expression and phytochemical profiles to generate a comprehensive model of rare or high value plants.

With multi-disciplinary R&D expertise, unique reverse engineering capabilities and game-changing techniques that enable re-engineering the chemical composition found in plants, e-Sense Lab re-formulates these for numerous commercial applications.

Cannabis is the first plant eSense is targeting for re-engineering. eSense is creating a cannabis plant that has all the characteristics of the real thing, but does not contain the psychoactive and more heavily regulated cannabinoid compound.

To learn more about eSense-Lab, please visit www.esense-lab.com